English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, August 23, 2022
中国生物制药(1177.HK)公布2022年中期业绩,收入上升5.9%至人民币151.94亿元
中國生物製藥(1177.HK)公布2022年中期業績,收入上升5.9%至人民幣151.94億元
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion
Thursday, July 22, 2021
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic
中国生物制药捐资捐物人民币1,000万元驰援河南抗灾防疫
中國生物製藥捐資捐物人民幣1,000萬元馳援河南抗災防疫
Monday, May 24, 2021
中国生物制药2021年首季归属于母公司持有者应占盈利飙升118.5%至人民币19.14亿元
中國生物製藥2021年首季歸屬於母公司持有者應佔盈利飆升118.5%至人民幣19.14億元
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
Tuesday, March 23, 2021
中国生物制药2020年度纯利逆势增至人民币27.7亿元

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575